The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

BACKGROUND: A randomized controlled pilot trial was conducted to assess if melanoma patients treated with immunotherapy had the number of grade 3 or 4 adverse events during treatment reduced by 50% using a tailored electronic patient-reported outcomes tool in addition to standard toxicity monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolstrup, Lærke K., Bastholt, Lars, Dieperink, Karin B., Möller, Sören, Zwisler, Ann-Dorthe, Pappot, Helle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599285/
https://www.ncbi.nlm.nih.gov/pubmed/33125537
http://dx.doi.org/10.1186/s41687-020-00255-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599285/
https://www.ncbi.nlm.nih.gov/pubmed/33125537
http://dx.doi.org/10.1186/s41687-020-00255-0

Ejemplares similares